← Leaderboards
Pyone Aye
Tulane University Of Louisiana
$9,310,598
Attributed
$9,310,598
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2M · FY2017–25$2.5M$1.9M$1.3M$625K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,310,598 · 2
By mechanism
N01$9,310,598 · 2
Top collaborators
No co-investigators on record.
Most similar at Tulane University Of Louisiana
Same institution · by research overlap
- Ivona Pandrea$33,088,190
- Ronald S. Veazey$44,796,137
- Andrew Lackner$2,812,668
- Chad J Roy$2,554,223
- Lee Hamm$10,754,844
Others in their field
Other Emerging Leaders on “Research Personnel”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Leonard Freedman · Leidos Biomedical Research, Inc.$557,978,666
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Joel A Lipkin · Four Points Technology, Llc$178,737,225
- Lynn Briscoe · Leidos Biomedical Research, Inc.$160,201,956
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$123,112,727
Research focus
Research PersonnelProgramsResourcesVaccinesAids VaccinesNational Institute Of Allergy And Infectious DiseaseVaccine EvaluationModalityNonhuman PrimateVaccine ResearchPreclinical EvaluationPrevention StrategyHiv VaccinePreclinical StudyVirusMaintenanceEvaluationImmunogenicityBreedingHousingEvaluation/TestingAids PreventionFlexibilityPrevent
Grant awards (23)
Simian Vaccine Evaluation Unit: Core Activities - Administrative and Technical Support$271,956
N01 · FY2025 · AI · contact PI
Assessment of Clinical Grade Near-Native Cleavage-Independent Trimer Protein Compared to Membrane-Bound mRNA Expression Coupled with Glycan Deletion, Restoration and Heterologous Boosting$248,861
N01 · FY2025 · AI · contact PI
Simian Vaccine Evaluation Unit: Maintenance of Nonhuman Primates$226,620
N01 · FY2025 · AI · contact PI
Potent Boosting of Tfh1 Cells to Enhance HIV-1 Vaccine Efficacy$1,540,805
N01 · FY2024 · AI · contact PI
Simian Vaccine Evaluation Unit: Core Activities - Administrative and Technical Support$265,662
N01 · FY2024 · AI · contact PI
Simian Vaccine Evaluation Unit: Maintenance of Nonhuman Primates$221,814
N01 · FY2024 · AI · contact PI
Simian Vaccine Evaluation Unit: Core Activities - Administrative and Technical Support$259,529
N01 · FY2023 · AI · contact PI
Simian Vaccine Evaluation Unit: Maintenance of Nonhuman Primates$217,151
N01 · FY2023 · AI · contact PI
Assessment of Clinical Grade Near-Native Cleavage-Independent Trimer Protein Compared to Membrane-Bound mRNA Expression Coupled with Glycan Deletion, Restoration and Heterologous Boosting$262,752
N01 · FY2022 · AI · contact PI
Simian Vaccine Evaluation Unit: Core Activities - Administrative and Technical Support$253,599
N01 · FY2022 · AI · contact PI
Simian Vaccine Evaluation Unit: Maintenance of Nonhuman Primates$212,558
N01 · FY2022 · AI · contact PI
Assessment of Clinical Grade Near-Native Cleavage-Independent Trimer Protein Compared to Membrane-Bound mRNA Expression Coupled with Glycan Deletion, Restoration and Heterologous Boosting$918,112
N01 · FY2021 · AI · contact PI
Simian Vaccine Evaluation Unit: Core Activities - Administrative and Technical Support$247,822
N01 · FY2021 · AI · contact PI
Simian Vaccine Evaluation Unit: Maintenance of Nonhuman Primates$208,101
N01 · FY2021 · AI · contact PI
SVEU - Core Activities - Administrative and Technical Support$80,237
N01 · FY2021 · AI · contact PI
Identifying correlates of protection afforded by (Delta)GY SIVmac239 attenuated virus vaccine$602,145
N01 · FY2020 · AI · contact PI
Simian Vaccine Evaluation Unit: Core Activities - Administrative and Technical Support$242,515
N01 · FY2020 · AI · contact PI
Simian Vaccine Evaluation Unit: Maintenance of Nonhuman Primates$203,707
N01 · FY2020 · AI · contact PI
SVEU - Core Activities - Administrative and Technical Support$78,125
N01 · FY2020 · AI · contact PI
Evaluation of the Immunogenicity of a Stabilized MD39 Env Glycoprotein Trimer when Delivered through a Novel Alum Slow Release Technology with or without Other Adjuvants$645,369
N01 · FY2019 · AI · contact PI
Identifying correlates of protection afforded by (Delta)GY SIVmac239 attenuated virus vaccine$323,743
N01 · FY2019 · AI · contact PI
Identifying correlates of protection afforded by (Delta)GY SIVmac239 attenuated virus vaccine$186,376
N01 · FY2018 · AI · contact PI
Identifying correlates of protection afforded by (Delta)GY SIVmac239 attenuated virus vaccine$1,593,039
N01 · FY2017 · AI · contact PI